Every trial has to be reviewed by an Institutional Review Board (IRB) before it can enroll ... An example that is familiar to many is the Tuskegee Syphilis Study, in which 400 low-income African ...

ON AIR AND ONLINE. CONGRESSIONAL LEADERS AND OTHER DIGNITARIES WILL COME OUT FOR THE FIRST EVER OFFICIAL STATE HOLIDAY FOR THE TUSKEGEE AIRMEN LAST MARCH, BOTH HOUSES OF THE FLORIDA STATE ...

By then, 128 men had died. PAUL J. RICHARDS / AFP via Getty Images Above, 94-year-old Herman Shaw, a survivor of the Tuskegee Syphilis Study, speaks at the White House in 1997. At the event ...

Is it time for the United States to create a new federal holiday to recognize the Tuskegee Airmen? It may be, as Florida becomes the latest state to deem Tuskegee Airman Day a state holiday.

Colonel James Harvey III, 101, is among the last few airmen and support crew who proved that a black unit — the 332nd Fighter Group of the Tuskegee Airmen — could fight as well as any other in World ...

Col. Shelton Ivan Ware. Ware was one of the last Tuskegee Airmen. His military service includes working on the Red Ball Express in World War II, providing critical supplies to allied troops in ...

Links to “Notable Graves” of Black, Latino and female veterans were scrubbed from Arlington National Cemetery’s website. Among the notables who were disappeared: Gen. Colin Powell, the first ...

It wasn’t until 1972, when a whistleblower leaked the story, that the study was finally shut down. By then, 128 men had died. Above, 94-year-old Herman Shaw, a survivor of the Tuskegee Syphilis ...

He is one of the last remaining original Tuskegee Airmen in the DMV. The Tuskegee airmen were Black pilots and flying units with the U.S. Army Air Forces. Their bravery and success paved the way ...

Shares of IRB Infrastructure Developers experienced a notable surge, climbing 3.54% to reach Rs 45.47 during today's session. The stock's movement is marked by a significant increase in trading ...

Vytala is actively enrolling subjects into an IRB approved study designed to assess Seracal's acceptance and clinical outcomes across a broader patient populations. Led by Dr. Carol Ireton-Jones ...